Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of the effects of citalopram and doxepin in patients with chronic obstructive pulmonary disease
IRCT20161023030452N2Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of citalopram and doxepin in major depressive disorder (MDD), anxiety disorder and chronic obstructive pulmonary disease (COPD), sponsored by Zanjan University of Medical Sciences. Started May 2021; status: completed.
02
Drugs
citalopramdoxepin
03
Conditions
major depressive disorder (MDD)anxiety disorderchronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on IRCT20161023030452N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20161023030452N2.